LUCEMYRA Drug Patent Profile
✉ Email this page to a colleague
When do Lucemyra patents expire, and what generic alternatives are available?
Lucemyra is a drug marketed by Uswm and is included in one NDA.
The generic ingredient in LUCEMYRA is lofexidine hydrochloride. Additional details are available on the lofexidine hydrochloride profile page.
Summary for LUCEMYRA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 68 |
| Clinical Trials: | 7 |
| Patent Applications: | 1,899 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for LUCEMYRA |
| What excipients (inactive ingredients) are in LUCEMYRA? | LUCEMYRA excipients list |
| DailyMed Link: | LUCEMYRA at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for LUCEMYRA
Generic Entry Date for LUCEMYRA*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LUCEMYRA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pharmacotherapies for Alcohol and Substance Abuse Consortium | Phase 2 |
| Michael E. DeBakey VA Medical Center | Phase 2 |
| United States Department of Defense | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for LUCEMYRA
US Patents and Regulatory Information for LUCEMYRA
LUCEMYRA is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of LUCEMYRA is See Plans and Pricing.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting LUCEMYRA
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Uswm | LUCEMYRA | lofexidine hydrochloride | TABLET;ORAL | 209229-001 | May 16, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
